Genscript Biotech (FRA:G51) Short-Term Capital Lease Obligation : €7.2 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Genscript Biotech Short-Term Capital Lease Obligation?

Genscript Biotech's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.2 Mil.

Genscript Biotech's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (€8.1 Mil) to Jun. 2024 (€13.4 Mil) but then declined from Jun. 2024 (€13.4 Mil) to Dec. 2024 (€7.2 Mil).

Genscript Biotech's annual Short-Term Capital Lease Obligation declined from Dec. 2022 (€10.5 Mil) to Dec. 2023 (€8.1 Mil) and declined from Dec. 2023 (€8.1 Mil) to Dec. 2024 (€7.2 Mil).

Genscript Biotech Short-Term Capital Lease Obligation Historical Data

The historical data trend for Genscript Biotech's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Short-Term Capital Lease Obligation Chart

Genscript Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.13

6.65

10.48

8.13

7.19

Genscript Biotech Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															10.48	8.72	8.13	13.43	7.19

Genscript Biotech Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Genscript Biotech Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (FRA:G51) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

GNNSF:USA 01548:Hong Kong

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.

Genscript Biotech Headlines

No Headlines